Austrian Hypertrophic Cardiomyopathy Registry

NCT06368518 | Recruiting DMC

• 1 other identifier: ID01/2024/MZHCM-Reg/NV
• Study Type: observational
• Target: 1,000
• Locations: 1 country
• Sites: 15

Brief Summary

The Austrian Hypertrophic Cardiomyopathy (HCM) Registry is a prospective, multicenter registry enrolling patients at multiple outpatient clinics across Austria including academic and non-academic centers. Patients will undergo a structured examination process including assessment for symptoms of HCM, past medical history, concomitant medication, family history and the presence of HCM-specific red flags. Furthermore, clinical data derived from electrocardiogram, echocardiography, laboratory analysis, and genetic testing will be collected focusing on a lean variable dictionary and, in addition, specific hypothesis-driven research parameters. All data are entered into an electronic case report form (eCRF) (Phoenix Clinical Trial Management System). In order to perform multicenter analyses, data can be extracted from the eCRF after approval by the steering committee.

Conditions

Hypertrophic Cardiomyopathy

Keywords

Hypertrophic Cardiomyopathy; Left ventricular hypertrophy; Hypertrophic Phenotype

Outcome Measures

Primary Outcomes (2)

• All cause mortality

  All cause mortality

  Through study completion, on average 20 years

• Cardiovascular events

  Cardiovascular events

  Through study completion, on average 20 years

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

The study population includes subjects who fulfill criteria of HCM and are treated in Austria.

You may qualify if:

• Patients admitted to the HCM outpatient clinic of participating centers of the HCM Registry
• Interventricular septal thickness ≥ 13 mm and cardiomyopathy-specific red flags OR Interventricular septal thickness ≥ 15 mm not explainable by loading conditions OR Interventricular septal thickness ≥ 17 mm
• Willingness and ability to provide signed informed consent form (ICF) prior to participation in any study-related procedures

You may not qualify if:

• Age \< 18 years
• Known cardiac amyloidosis

Sponsors & Collaborators

• Medical University of Graz: lead

Study Sites (15)

Kepler University Hospital Linz

Linz, Linz, 4021, Austria

RECRUITING

University Hospital St. Pölten

Sankt Pölten, Lower Austria, 3100, Austria

RECRUITING

Hospital Landesklinikum Wiener Neustadt

Wiener Neustadt, Lower Austria, 2700, Austria

RECRUITING

Paracelsus Medical University of Salzburg

Salzburg, Salzburg, 5020, Austria

RECRUITING

Clinic Cardinal Schwarzenberg

Schwarzach im Pongau, Salzburg, 5620, Austria

RECRUITING

Hospital Graz 2 West

Graz, Styria, 8020, Austria

RECRUITING

Medical University of Graz

Graz, Styria, 8036, Austria

RECRUITING

Medical University of Innsbruck

Innsbruck, Tyrol, 6020, Austria

RECRUITING

Hospital St. Josef Braunau

Braunau am Inn, Upper Austria, 5280, Austria

RECRUITING

Ordensklinikum Linz

Linz, Upper Austria, 4020, Austria

RECRUITING

Medical University of Vienna

Vienna, Vienna, 1090, Austria

RECRUITING

Favoriten Clinic Vienna

Vienna, Vienna, 1100, Austria

ACTIVE NOT RECRUITING

Klinik Ottakring

Vienna, Vienna, Austria

RECRUITING

General Hospital St. Johann in Tirol

Sankt Johann in Tirol, 6380, Austria

RECRUITING

Clinic Wels-Grieskirchen

Wels-Grieskirchen, 4600, Austria

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood samples

MeSH Terms

Conditions

Cardiomyopathy, Hypertrophic; Hypertrophy, Left Ventricular

Condition Hierarchy (Ancestors)

Cardiomyopathies; Heart Diseases; Cardiovascular Diseases; Aortic Stenosis, Subvalvular; Aortic Valve Stenosis; Aortic Valve Disease; Heart Valve Diseases; Cardiomegaly; Hypertrophy; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Nicolas D Verheyen, MD

CONTACT

004331638530173; nicolas.verheyen@medunigraz.at

Viktoria Santner, MD

CONTACT

004331638531233; viktoria.santner@medunigraz.at

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 20 Years
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: April 10, 2024
• First Posted: April 16, 2024
• Study Start: March 8, 2024
• Primary Completion (Estimated): March 1, 2044
• Study Completion (Estimated): March 1, 2044
• Last Updated: December 5, 2025

Record last verified: 2025-11

Locations

AU (15)